Company intelligence / Profile preview

Nuo Therapeutics (formerly Cytomedix)

Gaithersburg, Maryland, United Statescytomedixcorp.com ↗

Ownership: Private
Development stage: Commercial

Overview

Cytomedix (later Nuo Therapeutics) commercialized the AutoloGel System (rebranded as Aurix), which was FDA-cleared for use on a variety of exuding wounds. The company also had clinical programs including the RECOVER-Stroke trial with ALD-401 and the PACE study for Intermittent Claudication.

Therapeutic areas: EndocrinologyDermatologyRheumatologyCardiovascularNeurology
Modalities: Autologous platelet-rich plasma (PRP)Autologous stem cellsPlatelet-derived signal moleculesPlasma scaffolds
Industry: Biotech

Drug pipeline

3 assets

autologous platelet gel (National Healing Corporation)

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

National Heart, Lung and Blood Institute (for PACE study)

Beyond the preview

Go deeper on Nuo Therapeutics (formerly Cytomedix).

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nuo Therapeutics (formerly Cytomedix).

Explore the full profile